Dr. Fahar Merchant reports

MEDICENNA THERAPEUTICS APPOINTS DR. NAGEATTE IBRAHIM AS CHIEF MEDICAL OFFICER

Medicenna Therapeutics Corp. has appointed Dr. Nageatte Ibrahim, MD, as chief medical officer. Dr. Ibrahim will serve in a fractional capacity, bringing extensive clinical development and oncology expertise to support the advancement of the company's pipeline.

Dr. Ibrahim, former chief medical officer of oncology at Innovent Biologics USA, brings more than two decades of experience spanning oncology drug development, including over 12 years at Merck and GSK, and nine years in academia where she held faculty and clinical appointments at Harvard Medical School, Dana-Farber Cancer Institute and the Perelman School of Medicine at the University of Pennsylvania.

"We are thrilled to welcome Dr. Ibrahim to Medicenna at this pivotal stage of our clinical development," said Dr. Fahar Merchant, president and chief executive officer of Medicenna. "Her deep expertise in global oncology drug development, including leadership on multiple landmark immunotherapy programs, will be instrumental as we advance our IL-2 superagonist platform and expand our clinical pipeline with our first-in-class antiPD1-IL-2 bifunctional program. Trained as a physician and scientist, she played a pivotal role in the development of the world's best-selling oncology drug, pembrolizumab, an anti-PD1 immunotherapy that has changed the treatment landscape for many cancers. Nageatte is a natural fit for Medicenna's superkine immunotherapy pipeline, especially development of anti-PD1 bispecifics and the cancer indications being pursued by Medicenna in the MDNA11 Ability-1 trial. We are honoured to work with Nageatte who has helped bring anti-PD1 immunotherapy to patients around the world, changing the treatment paradigm for melanoma and other difficult-to-treat cancers."

"I am excited to partner with Medicenna and contribute to the advancement of its innovative cytokine-based immunotherapies," said Dr. Ibrahim. "The company's IL-2 superagonist programs, MDNA11 and MDNA113, hold promise to improve outcomes for patients with various solid tumours with bizaxofusp (MDNA55) demonstrating compelling evidence of efficacy in patients with glioblastoma, one of the most challenging cancers with significant unmet needs. I look forward to working with the team to accelerate the clinical development of these therapies."

Dr. Ibrahim most recently served as chief medical officer of oncology at Innovent Biologics USA, where she established and led a global clinical development organization and played a key role in building the company's United States presence. Prior to Innovent, she spent over a decade at Merck, where she advanced to vice-president of global clinical development, oncology. In that role, she led the strategic direction and execution of clinical programs for pembrolizumab across multiple tumour types and combination regimens.

During her tenure at Merck, Dr. Ibrahim led pivotal global registration studies supporting approvals of pembrolizumab in frontline metastatic and resectable advanced melanoma, and contributed to numerous additional global approvals across indications including Merkel cell carcinoma, gastric cancer, biliary tract cancer, hepatocellular carcinoma and pediatric neurofibromatosis type 1 (NF-1). Her work also supported tumour-agnostic approvals such as MSI-H/dMMR and TMB-H indications. Earlier in her career at GSK, she contributed to the development of the dabrafenib and trametinib combination therapy, which received global approvals in melanoma.

Dr. Ibrahim is widely recognized for her leadership in building high performing clinical teams and fostering collaborative, growth-oriented environments. She has also served as a scientific adviser to the Melanoma Research Alliance. In addition, she is the founder and chief executive officer of Arc Nouvel Clinical Development Consulting, a firm focused on advancing innovative therapeutics through all stages of clinical development, and their team of experts were the pioneers in bringing pembrolizumab to patients across many indications in oncology.

About Medicenna Therapeutics Corp.

Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 superkines and first-in-class empowered superkines. Medicenna's long-acting IL-2 superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna's first-in-class targeted PD-1 x IL-2 bispecific, MDNA113, is in development for solid tumours and was designed using the company's proprietary Biskits (bifunctional superkine immunotherapies) and T-Mask (targeted metalloprotease activated superkine) platforms. Medicenna's IL-4 empowered superkine, bizaxofusp (formerly MDNA55), has been studied in five clinical trials enrolling over 130 patients, including a phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained fast-track and orphan drug status from the FDA and FDA/EMA (European Medicines Agency), respectively.

We seek Safe Harbor.